Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHYSIOLYTE IN PLASTIC CONTAINER vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Physiolyte is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and correct fluid and electrolyte imbalances. The mechanism involves distribution of fluids between intravascular and interstitial spaces, with electrolytes contributing to osmotic balance and physiological functions.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Maintenance of fluid and electrolyte balance,Replacement of fluid and electrolyte losses in patients with dehydration or hypovolemia,Correction of mild metabolic acidosis (due to lactate or acetate buffer)
Hypertension
Intravenous infusion; dose determined by clinical condition (e.g., dehydration, electrolyte replacement). Typical adult: 500–1000 m L as a single infusion; rate based on clinical status.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
The terminal elimination half-life of the infused crystalloid components is not applicable as a single value; the half-life of water is approximately 30–60 minutes in healthy individuals, but varies with renal function. Electrolytes have longer half-lives (e.g., Na+ ~12–24 hours). Clinical context: In renal impairment, half-life is prolonged.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
The components of Physiolyte (sodium, chloride, potassium, calcium, magnesium, and acetate) are not metabolized; they are excreted primarily by the kidneys. Acetate is rapidly metabolized in the liver to bicarbonate.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Physiolyte is a balanced crystalloid solution; its components (electrolytes and water) are excreted primarily via renal elimination. Water is eliminated by kidneys (urine), lungs (insensible loss), and skin (sweat). Electrolytes (Na+, K+, Ca2+, Mg2+, Cl-, acetate, gluconate) are predominantly excreted renally with minimal biliary or fecal elimination (<5%).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
The components of Physiolyte (electrolytes) do not significantly bind to plasma proteins; protein binding is negligible (<5%).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Volume of distribution for crystalloid solutions is approximately 0.2–0.25 L/kg for water and electrolytes, corresponding to the extracellular fluid volume. Clinical meaning: Rapid redistribution from intravascular to interstitial space (about 75% leaves vasculature within 1 hour).
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Intravenous: 100% bioavailability. Not administered orally.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No specific dose adjustment; use with caution in renal impairment due to risk of fluid/electrolyte overload. Monitor serum electrolytes and renal function.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
No specific dose adjustment; use with caution in hepatic impairment due to potential fluid/electrolyte imbalances.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Intravenous infusion; dose determined by weight and clinical condition. Typical: 20–30 m L/kg as a single infusion; adjust based on ongoing losses and maintenance requirements.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and fluid status; adjust rate and volume as needed.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
Use with caution in patients with congestive heart failure, renal impairment, or conditions that may cause fluid overload,Monitor serum electrolytes, fluid balance, and renal function during therapy,Not recommended for use in neonates or infants without careful monitoring due to risk of hypernatremia,Avoid rapid or large-volume infusions in patients with compromised cardiovascular or renal function
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to any component,Severe renal impairment (anuria or oliguria),Hyperkalemia (for solutions containing potassium),Hypermagnesemia (for solutions containing magnesium),Hypercalcemia (for solutions containing calcium),Severe metabolic alkalosis,Concurrent administration with certain drugs that may cause adverse interactions (e.g., potassium-sparing diuretics, ACE inhibitors)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions. However, consider the patient's overall fluid and electrolyte status; avoid excessive intake of sodium or potassium-rich foods if electrolyte imbalances are present.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Physiolyte is a balanced electrolyte solution. No teratogenic effects reported. Considered low risk in all trimesters when used as directed.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Physiolyte is an electrolyte solution; its components are normal constituents of breast milk. M/P ratio not applicable. Considered compatible with breastfeeding.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No specific dose adjustments required for pregnancy. Monitor for altered fluid requirements due to physiologic changes.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Physiolyte (balanced electrolyte solution) is isotonic with plasma and contains acetate as a buffer. Do not administer with blood products due to risk of clotting. Monitor serum electrolytes, renal function, and fluid balance during infusion. Caution in patients with heart failure, renal impairment, or hyperkalemia.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
This solution is used to replace fluids and electrolytes in your body.,Tell your healthcare provider if you have kidney disease, heart disease, or are on a low-salt diet.,Report any signs of fluid overload: shortness of breath, swelling, or rapid weight gain.,Do not mix this solution with other medications unless directed by your provider.,This product is sterile and for single use only; discard any unused portion.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHYSIOLYTE IN PLASTIC CONTAINER vs ALDOCLOR-150, answered by our medical review team.
PHYSIOLYTE IN PLASTIC CONTAINER is a Irrigation Solution that works by Physiolyte is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and correct fluid and electrolyte imbalances. The mechanism involves distribution of fluids between intravascular and interstitial spaces, with electrolytes contributing to osmotic balance and physiological functions.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHYSIOLYTE IN PLASTIC CONTAINER and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHYSIOLYTE IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by clinical condition (e.g., dehydration, electrolyte replacement). Typical adult: 500–1000 m L as a single infusion; rate based on clinical status.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHYSIOLYTE IN PLASTIC CONTAINER and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHYSIOLYTE IN PLASTIC CONTAINER is classified as Category C. Physiolyte is a balanced electrolyte solution. No teratogenic effects reported. Considered low risk in all trimesters when used as directed.. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.